The diagnosis of Multiple Sclerosis (MS) is based on clinical findings that are characterized by sudden neurological deficits in different parts of the CNS. Dissemination of lesions in space and time is the basic criterion. MRI can demonstrate most precisely any changes in the water content of brain tissue thus making it a very sensitive diagnostic tool to detect inflammatory processes like MS plaques. The following will briefly summarize the diagnostic features and procedures and will assess the appearance of typical MS lesions, their localization and configuration, which are essential for diagnosis and follow up examinations. It will propose the preferred sequences and technical parameters for standardized baseline examinations and follow-ups.
BacelarODeVeraARadueEW: MS in MRI. A Learning CDROM. University Hospital Basel, Neuroradiology2004.
2.
BarkhofFFilippiMMillerD: Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain120: 2059–2069, 1997.
3.
BarkhofF: MRI in Multiple Sclerosis: Correlation with expanded disability status scale (EDSS). Multiple Scl5: 283–286, 1999.
4.
BastianelloS: Conventional magnetic resonance sequences in multiple sclerosis. Ital J Neurol Sci20 (5 Suppl): 229231, 1999.
5.
BotJCBarkhofFPolmanCH: Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology. Jan 27; 62 (2): 226–33, 2004.
6.
DeStefanoNNarayananSFrancisGS: Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol58: 6570, 2000.
7.
DichgansMGasserT: CADASIL: Klinische Aspekte und Diagnose. Dtsch Med Wochenschr123: 979–981, 1998.
8.
VasconcelosCC FerreiraSantosCM MirandaPapaisAlvarenga M: The reliability of specific primary progressive MS criteria in an ethnically diverse population. J Neurol Sci. Jul 15; 270 (12): 15964. Epub 2008 May 12, 2008.
9.
FilippiMRoccaMAMartinoG: Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol43: 809–814, 1998.
10.
HardmeierMWagenpfeilSFreitagP: European rIFN beta 1a in Relapsing MS Dose Comparison Trial Study Group. Atrophy is detectable within a 3 month period in untreated patients with active relapsing-remitting multiple sclerosis. Arch Neurol60: 1736–1739, 2003.
11.
KapposLPolmanCHFreedmanMS: Treatment with interferon beta 1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. Oct 10; 67 (7): 1242–9. Epub 2006 Aug 16, 2006.
12.
Kleinschmidt-DeMastersBK: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta 1a for multiple sclerosis. N Eng J Med2005: 353.
13.
KortewegTTintoréMUitdehaagB: MRI criteria for dissemination in space in patients with clinically isolated syndromes: A multicentre follow up study. Lancet Neurol Mar; 5 (3): 221–7, 2006.
14.
KortewegTBarkhofFUitdehaagBM: How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. Ann Neurol Apr; 57 (4): 606–7, 2005.
15.
KuhleJPohlCMehlingM: Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. Jan 25; 356 (4): 3718, 2007.
16.
Langer-GouldA: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med2005: 353.
17.
LucchinettiCFBrückWRodriguezM: Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol6: 259–274, 1996.
18.
LucchinettiCBrückWParisiJ: Heterogenity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol47: 707–717, 2000.
19.
a'NijeholtGJ LycklamaBarkhofFScheltensP: MR of the spinal cord in multiple sclerosis: Relation to clinical subtype and disability. Am J Neuroradiol18: 1041–1048, 1997.
20.
MatthewsPMDeStefanoNNarayananS: Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin Neurol18: 327–336, 1998.
21.
McDonaldWCompstonAEdanG: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol50: 121–127, 2001.
22.
McDonaldWICompstonAEdanG: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol Jul;50 (1): 121–7, 2001.
23.
MuellerLenke NRadueEWvan BuchemM: Guidelines for the evaluation of MR images in patients with multiple sclerosis, potentially at risk for progressive multifocal leukoencephalopathy: Consensus reading by expert MRI panel. Posterpresentation on ECTRIMS/ACTRIMS Sept 2005.
24.
NielsenJMKortewegTBarkhofF: Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol Nov;58 (5): 781–3, 2005.
25.
O'RiordanJIThompsonAJKingsleyDPE: The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10 year follow up. Brain121: 495–503, 1998.
26.
PolmanCHReingoldSCEdanG: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. Dec, 58 (6): 840–6, 2005. Review.
27.
PolmanCHWolinskyJSReingoldSC: Multiple sclerosis diagnostic criteria: Three years later. Mult Scler Feb;11 (1): 512, 2005, Review.
28.
PostJ: Progressive multifocal leukoencephalopathy in AIDS: Are there any MR findings useful to patient management and predictive of patient survival?AM J Neuroradiol20: 1896–1906, 2005.
29.
RadueEWDeVeraABacelarO: Differenzierte MRT-Befundung zur Diagnosestellung der Multiplen Sklerose. Standardisierung der MRT Untersuchung. Klin Neuroradiol2004: Nr. 4.
30.
RudickRAFisherELeeJC: Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology53: 1698–1704, 1999.
SwantonJKRoviraATintoreM: MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol Aug; 6 (8): 677–86, 2007.
33.
ThorpeJWKiddDMoseleqIF; Serial gadoliniumenhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis. Neurology46: 373–378, 1996.
34.
TintoréMRoviraAMartinezM: Isolated demyelinationg syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol21: 702–706, 2000.
35.
TruyenLVan WaesbergheJHVan WalderveenMA: Accumulation of hypointense lesions (black holes) on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology47: 1469–1476, 1996.
36.
TubridyNMolyneuxPDMoseleyIF: The sensitivity of thin slice fast spin echo, fast FLAIR and gadolinium enhanced T1-weighted MRI sequences in detecting new lesion activity in multiple sclerosis. J Neurol246: 1181–1185, 1999.
37.
UitdehaagBMKapposLBauerL: Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler Apr;11 (2): 227–31, 2005.
38.
Van WalderveenMAKamphorstWScheltensP: Histopathologic correlate of hypointense lesions on T1.weighted spin echo MRI in multiple sclerosis. Neurology50: 1282–1288, 1998.
39.
Van WalderveenMABarkhofFPauwelsPJ: Neuronal damage in T1 hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol46: 79–7, 1999.
40.
WerringDJClarkCABarkerGJ: Diffusion tensor imaging of lesions and normal appearing white matter in multiple sclerosis. Neurology52: 1626–1632, 1999.
41.
YousryTAGrossmanRIFilippiM: Assessment of posterior fossa damage in MS using MRI. J Neurol Sci15: 50–53, 2000. Review.
